Navigation Links
AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012

REDWOOD CITY, Calif., Aug. 7, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second quarter 2012 financial results after market close on Thursday, August 9, 2012. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on August 9, 2012 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (800) 860-2442 for domestic callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's website at

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company's website at

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. AcelRx plans to initiate a Phase 2 study, pending protocol approval, for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC. For additional information about AcelRx's clinical programs please visit

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the success of its patent prosecution strategy; its ability to protect its proprietary technology, including the risks that pending patent applications may not result in issued patents; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q for the three months ended March 31, 2012. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The recently published 32nd Annual Report of ... that in 2014, someone called a poison center about every 11 seconds. America’s ... human exposure cases. , The American Association of Poison Control Centers (AAPCC) maintains ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast ... and prevention—is joining forces with the award-winning creator and writer of Downton Abbey ... 7, 2015 at the Union League of Philadelphia. , The benefit, titled ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about ... baby had high blood pressure due to loud noises," she said, "so I decided ... noise pollution as well as radio waves and microwaves." , The baby BABY MUFF ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
Breaking Medicine News(10 mins):